Literature DB >> 1671892

Co-trimoxazole for childhood febrile illness in malaria-endemic regions.

P B Bloland1, S C Redd, P Kazembe, R Tembenu, J J Wirima, C C Campbell.   

Abstract

The efficacy of co-trimoxazole for the treatment of Plasmodium falciparum parasitaemia in children younger than 5 years of age was evaluated in Malawi. 46 children with P falciparum parasitaemia, 37% of whom also met clinical criteria for a diagnosis of acute lower respiratory tract infection, were treated with 20 mg/kg co-trimoxazole twice daily for five days. Parasitaemia (mean clearance time 2.7 days) and symptoms were rapidly abolished and improvement was maintained during follow-up for 14 days. Co-trimoxazole may be an effective single treatment for febrile illness in young children in areas where malaria is endemic, resources are few, and diagnosis must rely on clinical findings alone.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1671892     DOI: 10.1016/0140-6736(91)91299-a

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  15 in total

1.  Effects of body temperature on respiratory rate in young children.

Authors:  H Campbell; P Byass; T J O'Dempsey
Journal:  Arch Dis Child       Date:  1992-05       Impact factor: 3.791

2.  Economic implications of resistance to antimalarial drugs.

Authors:  M Phillips; P A Phillips-Howard
Journal:  Pharmacoeconomics       Date:  1996-09       Impact factor: 4.981

Review 3.  Acute respiratory infection: a global challenge.

Authors:  H Campbell
Journal:  Arch Dis Child       Date:  1995-10       Impact factor: 3.791

Review 4.  Drug interactions in the treatment and chemoprophylaxis of malaria in HIV infected individuals in sub Saharan Africa.

Authors:  Fatai A Fehintola; Olusegun O Akinyinka; Isaac F Adewole; Chiedza C Maponga; Qing Ma; Gene D Morse
Journal:  Curr Drug Metab       Date:  2011-01       Impact factor: 3.731

5.  Evaluation of an algorithm for integrated management of childhood illness in an area of Kenya with high malaria transmission.

Authors:  B A Perkins; J R Zucker; J Otieno; H S Jafari; L Paxton; S C Redd; B L Nahlen; B Schwartz; A J Oloo; C Olango; S Gove; C C Campbell
Journal:  Bull World Health Organ       Date:  1997       Impact factor: 9.408

6.  Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.

Authors:  A S Walker; D Ford; C F Gilks; P Munderi; F Ssali; A Reid; E Katabira; H Grosskurth; P Mugyenyi; J Hakim; J H Darbyshire; D M Gibb; A G Babiker
Journal:  Lancet       Date:  2010-03-27       Impact factor: 79.321

Review 7.  CNS adverse events associated with antimalarial agents. Fact or fiction?

Authors:  P A Phillips-Howard; F O ter Kuile
Journal:  Drug Saf       Date:  1995-06       Impact factor: 5.606

8.  Cotrimoxazole in the treatment of acute uncomplicated falciparum malaria in nigerian children : a controlled clinical trial.

Authors:  F A Fehintola; A A Adedeji; E Tambo; B B Fateye; T C Happi; A Sowunmi
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

9.  In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs.

Authors:  P A Winstanley; E K Mberu; I S Szwandt; A M Breckenridge; W M Watkins
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

10.  In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from the Kenyan coast: emergence of parasites with Ile-164-Leu mutation.

Authors:  Steven M Kiara; John Okombo; Victor Masseno; Leah Mwai; Isabella Ochola; Steffen Borrmann; Alexis Nzila
Journal:  Antimicrob Agents Chemother       Date:  2009-06-15       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.